Kevin McVary, MD
Urology · Springfield, ILNPI 1356369185
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $252,137 of the $372,316 with a category attached, or 67.7%. 10 manufacturers reported payments, led by SRS Medical Systems, Inc. at 42.3% of the total. Among urology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 206 payments — averaging $1807.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SRS Medical Systems, Inc.$158K
- Boston Scientific$154K
- Sumitomo Pharma America, Inc.$18K
- Sanofi-aventis U.S. LLC$16K
- Olympus America Inc.$12K
- Purdue Pharma L.p.$7K
- plus $8K from 4 others
Across 41 payments — averaging $3790.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$128K
- Astellas Pharma Global Development$15K
- Sumitomo Pharma America, Inc.$13K
What the payments were for
- Consulting fees$252,13768%
- Speaking & faculty fees$100,50627%
- Travel & lodging$16,2314%
- Food & beverage$3,4431%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SRS Medical Systems, Inc. | 7 | $157,500 |
| Boston Scientific | 149 | $153,977 |
| Sumitomo Pharma America, Inc. | 7 | $17,871 |
| Sanofi-aventis U.S. LLC | 10 | $15,936 |
| Olympus America Inc. | 22 | $12,363 |
| Purdue Pharma L.p. | 1 | $6,600 |
| Laborie Medical Technologies Corp. | 4 | $4,120 |
| Antares Pharma, Inc. | 4 | $3,816 |
| I/o Urology Corp. | 1 | $117 |
| Coloplast | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroCuff$90,000
- GENERAL BPH$52,140
- REZUM$45,237
- CT3000 Pro Base Unit$45,000
- UroCuff-DC Disposable, Single$45,000
- Spanner Prothetic Stent$22,500
- GEMTESA$17,831
- GREENLIGHT$14,409
- GENERAL - THERAPIES$13,582
- rezum Generator$11,906
- Olympus Resection Disposables$11,900
- Optilume BPH Drug Coated Balloon Catheter$4,120
- NOCDURNA$3,772
- LithoVue$170
- CarePath$117
How this compares
$372,316 in reported general payments places this provider in the 95th percentile of 550 urology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 64 | $77,007 |
| GemtesaVibegron | 18 | $21,832 |
| Testosterone | 61 | $6,682 |
| Tamsulosin Hcl | 275 | $5,513 |
| Bethanechol Chloride | 55 | $5,074 |
| Silodosin | 22 | $1,927 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 60 | $1,461 |
| Cabergoline | 25 | $936 |
| Pentoxifylline | 13 | $602 |
| Finasteride | 38 | $547 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 43 | $62 |
| Sildenafil Citrate | 17 | $57 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $17,871 | $21,83218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 550 urology providers in Illinois.
Other urology in Springfield
- Robert NadlerSpringfield$70K
- Bradley SchwartzSpringfield$45K
- Mark BrandtPark Ridge$1.3M
- Aaron BergerChicago Ridge$583K
- Gary SteinbergChicago$529K
- Simone CrivellaroChicago$526K
- Brian HelfandChicago$517K
- Ashley RossChicago$404K
- Richard HarrisMelrose Park$363K
- Amy KrambeckChicago$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.